Lipitor and Heart Disease

What It Covers

Lipitor (atorvastatin) became history's most profitable drug, generating $125 billion by treating high cholesterol to prevent heart disease. The episode examines how Framingham Heart Study established cholesterol as a risk factor, how statins were discovered from Japanese mold research, and why 90 million Americans now take these drugs despite controversial evidence about their actual benefit for prevention.

Key Questions Answered

• •Risk Factor Discovery: The Framingham Heart Study, launched in 1948 after FDR's death from stroke, identified five measurable predictors of heart disease: age, sex, blood pressure, cholesterol level, and smoking status. This created a new paradigm in medicine focused on prevention rather than just treating symptoms, allowing doctors to calculate a patient's 10-year risk score and intervene before disease develops.
• •Statin Development: Japanese chemist Akira Endo discovered the first statin (mevastatin) in 1971 by isolating compounds from blue-green mold found on old rice in Kyoto. After five years of testing, his work led to lovastatin's FDA approval in 1986, followed by atorvastatin in 1997. Atorvastatin proved more effective than earlier statins, reducing LDL cholesterol 39-60 percent and earning the nickname turbostatin among pharmaceutical insiders.
• •Marketing Revolution: Pfizer spent over $2 billion on direct-to-consumer advertising in 1997 when FDA rules changed, generating $22 return for every $1 spent. The company deployed 7,000 salespeople, launched the Know Your Numbers campaign, priced Lipitor below competitors despite superior efficacy, and ran ads during ER to reach target demographics. This consumer product approach transformed atorvastatin into the most prescribed drug in United States history.
• •Guideline Expansion: Clinical guidelines for statin prescriptions dropped from cholesterol scores of 260 in early years to 160 by 1997, then expanded further in 2001, 2004, and 2013. Each revision added millions more eligible patients, reaching 56 million Americans by 2013. Many committee members setting these guidelines received funding from Pfizer and other drugmakers, creating conflicts of interest that went undisclosed in official recommendations.
• •Number Needed to Treat: For every 100 people taking statins for five years, only one or two avoid a heart attack they might have otherwise had, meaning 98-99 people receive no benefit. This contrasts sharply with other medications: ibuprofen has a number needed to treat of four, antidepressants five. As guidelines expanded to include lower-risk patients, the ratio worsened from 40 under older standards to 100 currently.
• •Side Effects Reality: Original clinical trials reported only two percent of patients stopped statins due to side effects, primarily muscle pain and weakness. Observational studies of real-world use found 10 percent of patients quit due to subjective complaints, five times higher than trial data. With 90 million Americans taking statins, this means nine million people experience side effects severe enough to discontinue medication, far exceeding pharmaceutical company projections.